ACM
REVB icon

Altium Capital Management’s Revelation Biosciences REVB Stock Holding History

Altium Capital Management’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6
Closed -$48.4K – 90
2023
Q1 		$48.4K Buy
+6
New +$162K 0.03% 64

Other funds holding REVB

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Altium Capital Management's REVB Position: Q2 2023 in Review

Altium Capital Management sold out of Revelation Biosciences (REVB) in Q2 2023, closing a stake of 6 shares — an estimated $48.4K sold.

Altium Capital Management first reported a position in REVB in Q1 2023 and held it in 1 quarter. The position peaked at $48.4K in Q1 2023. 5 funds tracked by Wall St. Rank hold REVB as of Q2 2023.

  • Altium Capital Management reported no remaining Revelation Biosciences position as of Q2 2023 after selling out during the quarter.
  • Altium Capital Management sold 6 Revelation Biosciences shares in Q2 2023, an estimated $48.4K.
  • Altium Capital Management first reported a position in Revelation Biosciences in Q1 2023 and held it in 1 quarter.
  • Altium Capital Management's Revelation Biosciences position peaked at $48.4K in Q1 2023.
  • 5 funds tracked by Wall St. Rank held Revelation Biosciences as of Q2 2023.

Based on Altium Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.